|
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
<b>Background:</b> By targeting the prostate-specific membrane antigen (PSMA) on prostate cancer (PCa) cells PSMA-PET/CT shows great potential in locating the site of biochemical recurrence even at low PSA (Prostate-specific antigen)-levels.
|
28529650 |
2017 |
|
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
<b>Background:</b> This study sought to ascertain whether there is an association between prostate cancer (PC)-specific mortality (PCSM) and timing of salvage androgen deprivation therapy (ADT) among men with short versus long prostate-specific antigen doubling times (PSA-DTs).
|
29891524 |
2018 |
|
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
<b>Conclusions</b>: Early assessment of PSA after surgery is important for predicting radiographic progression in node-positive prostate cancer patients.
|
31258727 |
2019 |
|
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
<b>Expert opinion</b>: Multiparametric magnetic resonance imaging (mpMRI) and subsequent-targeted biopsy have improved the diagnostic accuracy of PCa detection in men with an elevated or rising serum PSA.
|
31277551 |
2019 |
|
Prostate carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
<b>Methods:</b> A Markov model of prostate cancer onset and progression was used to estimate the health and economic consequences of <sup>18</sup>F-choline PET/mpMRI for the detection of primary prostate cancer with a Gleason score of greater than or equal to 3 + 4 in men with elevated prostate-specific antigen levels.
|
31350321 |
2019 |
|
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
<b>Methods:</b> We conducted a prospective survey of physicians (NCT02940262) who referred 161 patients with prostate cancer BCR (median prostate-specific antigen value, 1.7 ng/mL; range, 0.05-202 ng/mL).
|
29242398 |
2018 |
|
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
<b>Objectives:</b> To report feasibility, early toxicity, and PSA kinetics following gantry-based, stereotactic radiotherapy (SBRT) boost within a prospective, phase 2, multicenter study (PROMETHEUS: ACTRN12615000223538).
|
31001481 |
2019 |
|
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
<b>Purpose:</b> Prostate-specific antigen (PSA) is a sensitive but unspecific marker for prostate cancer (PC) detection, which may result in harms including overdiagnosis and overtreatment.
|
31692391 |
2020 |
|
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
<b>Result:</b> The integrated device has wide liner detection ranges (0.05-25 ng/mL for both PSA and VEGF, and 5-300 cells/mL for PCa CTC), as well as high levels of sensitivity and selectivity, and demonstrated a high correlation with an enzyme-linked immunosorbent assay for sample detection in patients.
|
29158826 |
2017 |
|
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
<sup>18</sup>F-Fluorocholine PET/MRI in Restaging of Prostatic Carcinoma in Relation to PSA Level and Detection of Active Disease.
|
29970541 |
2018 |
|
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
<sup>68</sup>Ga-PSMA-11 PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy and PSA <0.5 ng/ml. Efficacy and impact on treatment strategy.
|
29905907 |
2019 |
|
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
(1) To characterise variation in general practitioners' (GPs') accounts of communicating with men about prostate cancer screening using the prostate-specific antigen (PSA) test, (2) to characterise GPs' reasons for communicating as they do and (3) to explain why and under what conditions GP communication approaches vary.
|
29362252 |
2018 |
|
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
(2) Elevated PCA3 as a requirement for biopsies in addition to PSA would have saved 37 (cutoff ≥ 25) or 43 (cutoff ≥ 35) of the 68 biopsy sessions, and 7 or 11 PCs would have been missed, respectively, including multiple high-risk PCs.
|
25746941 |
2015 |
|
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
(4) Conclusions: Gene‒PSA-guided personalized screening for PrCa leads to fewer unnecessary PSA tests without compromising the benefits of mortality reduction (as happens with the universal screening program).
|
31450602 |
2019 |
|
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
150 men with suspected prostate cancer (abnormal digital rectum examination and or elevated prostate-specific antigen) received pre-biopsy 3T mpMRI and were recruited into peer-reviewed, protocol-based prospective study.
|
29662622 |
2018 |
|
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
1634 participants had ⩾3 PSA readings of whom 174 underwent PB and 45 PrCas diagnosed.
|
29301143 |
2018 |
|
Prostate carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
18F-choline positron emission tomography/computed tomography for the detection of prostate cancer relapse: assessment of maximum standardized uptake value correlation with prostate-specific antigen levels.
|
31568268 |
2019 |
|
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
22 patients with elevated PSA and biopsy proven prostate carcinoma who underwent MRI of the prostate at 1.5 T with an endorectal coil were included.
|
30209952 |
2018 |
|
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
29h also reduces the expression of PSA, the biomarker of prostate cancer.
|
29448139 |
2018 |
|
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
3p13 deletions were linked to adverse features of prostate cancer, including advanced stage (p < 0.0001), high Gleason grade (p = 0.0125), and early PSA recurrence (p = 0.0015).
|
23794398 |
2013 |
|
Prostate carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
41 patients were treated for low-intermediate risk prostate cancer with initial prostate-specific antigen of ≤20 ng ml<sup>-1</sup>, Gleason score 6-7.
|
29338305 |
2018 |
|
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
8p loss concurrent with 8c gain may successfully predict disease recurrence and poor clinical outcome before the observation of detectable postoperative PSA values in patients with prostate cancer.
|
10792100 |
2000 |
|
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Prostate cancer diagnosis in the new millennium: strengths and weaknesses of prostate-specific antigen and the discovery and clinical evaluation of prostate cancer gene 3 (PCA3).
|
19154510 |
2009 |
|
Prostate carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Prostate cancer risk stratification using prostate specific antigen and genotype could improve prostate specific antigen test performance.
|
19450841 |
2009 |
|
Prostate carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Prostate cancer progression was defined as biochemical recurrence based on posttreatment prostate-specific antigen levels of >0.3 ng/mL for radical prostatectomy patients or a 2-ng/mL increase above the nadir for radiation therapy patients, initiation of hormone treatment, or metastases.
|
20651075 |
2010 |